Please login to the form below

Not currently logged in
Email:
Password:

Icon boost medical device trial capability with Aptiv acquisition

Deal will also enhance the CRO's position inadaptive trials and in Japan

Dublin-based contract research organisation Icon has acquired Aptiv Solutions for $143.5m, boosts its capabilities to run adapative and medical device trials.  

The deal will also expand Icon's footprint in Japan, allowing it to combine its existing operations in Tokyo and Osaka with Niphix, a full-service oncology-focused CRO owned by Aptiv.  

Dr Nuala Murphy, president of Icon Clinical Research Services, said: “Icon's market-leading innovation is helping our customers to reduce the time and cost of drug development.  

“Aptiv Solutions' adaptive trial capabilities will further differentiate and enhance our services to help our customers identify the most promising drug candidates earlier. Their presence in Japan will also broaden our existing capabilities in this market.”  

Icon's acquisition of Aptiv comes some six weeks after the US-headquartered CRO teamed up with Novartis, Janssen and Lilly to form a consortium to work on adaptive dose finding trials.  

The ADDPLAN DF Consortium partners will collaborate on developing new statistical methodologies for the design of innovative dose-finding clinical trials, with an emphasis on adaptive designs.  

It's an area European regulators are planning to look at in more details soon, when they launch an adaptive licensing pilot.

Article by
Dominic Tyer

2nd April 2014

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GK Strategy

GK is award-winning independent communications agency specialising in delivering impactful strategies for clients across the healthcare market....

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics